...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection
【24h】

Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection

机译:关节腔内注射塞来昔布的PEA微球可作为自动调节药物递送系统

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, we investigated the potential of celecoxib-loaded polyester amide (PEA) microspheres as an autoregulating drug delivery system for the treatment of pain associated with knee osteoarthritis (OA). Celecoxib release from PEA microspheres and inflammation responsive release of a small molecule from PEA was investigated in vitro. Inflammation responsive release of a small molecule from PEA was observed when PEA was exposed to cell lysates obtained from a neutrophil-like Hl-60 cell line. Following a short initial burst release of similar to 15% of the total drug load in the first days, celecoxib was slowly released throughout a period of >80 days. To investigate biocompatibility and degradation behavior in vivo, celecoxib-loaded PEA microspheres were injected in OA-induced (ACLT+ pMMx) or contralateral healthy knee joints of male Lewis rats. Bioactivity of celecoxib from loaded PEA microspheres was confirmed by PGE(2) measurements in total rat knee homogenates. Intra-articular biocompatibility was demonstrated histologically, where no cartilage damage or synovial thickening and necrosis were observed after intra-articular injections with PEA microspheres. Degradation of PEA microspheres was significantly higher in OA induced knees compared to contralateral healthy knee joints, while loading the PEA microspheres with celecoxib significantly inhibited degradation, indicating a drug delivery system with auto regulatory behavior. In conclusion, this study suggests the potential of celecoxib-loaded PEA microspheres to be used as a safe drug delivery system with auto regulatory behavior for treatment of pain associatedwith OA of the knee. (C) 2016 Elsevier B.V. All rights reserved.
机译:在这项研究中,我们调查了载有塞来昔布的聚酯酰胺(PEA)微球作为自动调节药物递送系统治疗与膝骨关节炎(OA)相关的疼痛的潜力。体外研究了塞来昔布从PEA微球的释放以及小分子从PEA的炎症反应性释放。当PEA暴露于得自嗜中性粒细胞样的H-1-60细胞系的细胞裂解液时,观察到小分子从PEA的炎症响应释放。在开始的几天内,最初的短暂突释释放量约占总药物负荷的15%,然后塞来昔布在> 80天内缓慢释放。为了研究体内的生物相容性和降解行为,将塞来昔布的PEA微球注射到雄性Lewis大鼠的OA诱导(ACLT + pMMx)或对侧健康的膝关节中。塞来昔布从装载的PEA微球的生物活性通过PGE(2)测量在总大鼠膝盖匀浆中得到证实。关节内生物相容性在组织学上得到证实,在关节内注射PEA微球后未观察到软骨损伤或滑膜增厚和坏死。与对侧健康的膝关节相比,OA诱发的膝盖中PEA微球的降解显着更高,而用celecoxib填充PEA微球则显着抑制了降解,表明药物输送系统具有自动调节性能。总之,这项研究表明载有塞来昔布的PEA微球有可能被用作具有自动调节行为的安全药物输送系统,以治疗与膝关节炎有关的疼痛。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号